{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-130436","form_type":"8-K","ticker":"HURA","cik":"0001498382","company_name":"TuHURA Biosciences, Inc./NV","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.598218+00:00","generated_at":"2026-05-29T18:48:50.232449+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TuHURA plans IFx-2.0 Phase 3 trial under SPA; signs non-binding LOI to acquire Kineta's KVA12123","bullets":["IFx-2.0 Phase 3 accelerated approval trial in first-line MCC to start H1 2025 under FDA SPA, with ORR primary and PFS secondary endpoints.","Non-binding LOI with Kineta to acquire KVA12123 VISTA antibody via merger; definitive agreement targeted Q4 2024.","Cash runway expected to fund operations late into H2 2025; $31M from Kintara merger plus $5M for Kineta exclusivity.","Hired Peter O'Neill as VP Clinical Operations and Michael Krsulich as Head of Quality Assurance.","REM-001 photodynamic therapy study for cutaneous metastatic breast cancer enrollment expected to complete Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-130436","json":"https://secwatch.observer/filing/0000950170-24-130436.json","markdown":"https://secwatch.observer/filing/0000950170-24-130436.md","text":"https://secwatch.observer/filing/0000950170-24-130436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/0000950170-24-130436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/hura-20241125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T18:48:50.232449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}